ArticleThe Canadian journal of urology2020
Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results.
Article in The Canadian journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03123250 (Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Complication rate across the minimally invasive surgical treatments (MISTs): where do we stand? A systematic review of the literature.Prostate cancer and prostatic diseases · 2025Pooled it
- Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.World journal of urology · 2022Pooled it
- Management of clinical failure after minimally invasive surgical therapies (MIST) for BPH: repeat MIST versus resection, enucleation or ablation-a narrative review from EAU endourology.World journal of urology · 2026Review
- Outcomes of aquablation: pooled analysis from the WATER, WATER II, OPEN WATER, FRANCAIS WATER, and JAPAN PMS studies.World journal of urology · 2025Article
- WATER versus WATER II 5-year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30-80-cmBJUI compass · 2024Article
- Aquablation in men with benign prostate hyperplasia: A systematic review and meta-analysis.Current urology · 2023Article
- Updates on Preprocedural Evaluation and Patient Selection for Prostatic Artery Embolization.Seminars in interventional radiology · 2022Review
- Laser enucleation of the prostate in men with very large glands ≥175 ml: A systematic review.Annals of medicine and surgery (2012) · 2022Review
- Technique, outcome and changes in prostate dimensions in patients with urinary retention managed by aquablation.International urology and nephrology · 2022Article
- Minimally Invasive Therapies for Benign Prostatic Obstruction: A Review of Currently Available Techniques Including Prostatic Artery Embolization, Water Vapor Thermal Therapy, Prostatic Urethral Lift, Temporary Implantable Nitinol Device and Aquablation.Cardiovascular and interventional radiology · 2022Review
- Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results.BJUI compass · 2022Article
- [Minimally invasive treatment options for the management of benign prostatic hyperplasia].Der Urologe. Ausg. A · 2021Article
- Evolution of AquablationVR-From innovation to establishment.Turkish journal of urology · 2021Article
- Reasons to overthrow TURP: bring on Aquablation.World journal of urology · 2021Review
- WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80-cmEuropean urology open science · 2021Article
- [Robotics and intraoperative navigation].Der Urologe. Ausg. A · 2021Review
- Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies.BMJ surgery, interventions, & health technologies · 2021Article
- [A (new) revolution in the treatment of benign prostatic hyperplasia? Aqua-ablation and prostate embolization].Der Urologe. Ausg. A · 2020Review
Corrections and comments
- Commented on by
Authors and funding
24 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo report 2-year safety and effectiveness of the Aquablation procedure for the treatment of men with symptomatic benign prostatic hyperplasia (BPH) and large-volume 80-150 cc prostates. MATERIALS AND
methodsBetween September-December 2017, 101 men with moderate-to-severe BPH symptoms and prostate volumes of 80-150 cc underwent an ultrasound-guided robotically executed Aquablation procedure in a prospective multicenter international clinical trial (WATER II). Baseline, procedural and follow up parameters were recorded at baseline and scheduled postoperative visits. Herein we report 2-year safety and efficacy for this cohort.
resultsMean prostate volume was 107 cc (range 80-150 cc). Mean IPSS improved from 23.2 at baseline to 5.8 at 2 years (17-point improvement, p < .0001). Mean IPSS quality of life improved from 4.6 at baseline to 1.1 at 2 years (p < .0001). Maximum urinary flow increased from 8.7 to 18.2 cc/sec. Two subjects underwent a repeat procedure for BPH symptoms over the 2-year follow up period. By 2 years or study exit, all but 2 of 74 subjects stopped taking alpha blockers. Similarly, all but 4 of 32 subjects stopped taking 5α-reductase inhibitors.
conclusionsTwo-year prospective multicenter follow up demonstrated that the Aquablation procedure is safe and effective in the treatment of men with LUTS due to BPH and prostates 80-150 cc with durable treatment efficacy, acceptable safety profile and a low retreatment rate. ClinicalTrials.gov number, NCT03123250.
Indexed as
Identifiers
32333733W3211704035What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.